Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival...

Authors :: Sokolova, Alexandra
Graff, Julie N.
Smith, Claire E
Beer, Tomasz M.
Latour, Emile
Grivas, Petros
Schweizer, Michael Thomas
Higano, Celestia S.
Alumkal, Joshi J.
Vuky, Jacqueline
Yu, Evan Y.
Cheng, Heather H.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5047-5047, 1p
Publication Year :: 2023

Full Text Access

Tools